Brain Natriuretic Peptide Testing

Number: 0618

  1. Aetna considers measurement of plasma brain natriuretic peptide (BNP) medically necessary to differentiate dyspnea due to heart failure from pulmonary disease.

  2. Aetna considers serial measurements of plasma BNP and/or its inactive metabolite, N-terminal pro-BNP (NT-proBNP), experimental and investigational for all other indications, including any of the following, because the clinical value of their measurements for these indications has not been established.

  • As a cardiovascular biomarker in healthy normal subjects; or
  • As a prognostic biomarker for the presence of diastolic dysfunction related to anemia in persons with sickle cell disease (NT-proBNP only); or
  • As a prognostic biomarker for the risk of incident of type 2 diabetes; or 
  • As a prognostic marker for individuals with structural congenital heart disease; or
  • For detecting early cardiac dysfunction in individuals with tetralogy of Fallot; or
  • For determining prognosis of members after an acute coronary syndrome episode; or
  • For determining prognosis of members with chronic heart failure; or
  • For diagnosing cardio-embolic stroke; or
  • For diagnosing patent ductus arteriosus; or
  • For guiding statin decisions for members with heart failure; or
  • For guiding the initiation of thrombolytic therapy in members with acute pulmonary embolism; or
  • For identifying stress-induced myocardial ischemia; or
  • For managing (diagnostic, prognostic and therapeutic) members with chronic renal failure; or
  • For monitoring the effectiveness of therapy for members with congestive heart failure; or
  • For prediction of fatal outcome after stroke; or
  • For prediction of the occurrence of atrial fibrillation after cryptogenic stroke; or
  • For pre-operative cardiac risk assessment in non-cardiac surgery (e.g., predicting adverse cardiovascular outcomes following non-cardiac surgery); or
  • For routine evaluation of dyspnea, other than where necessary to distinguish heart failure from pulmonary disease; or
  • For screening unrecognized left ventricular dysfunction; or
  • For titrating therapy for members with chronic heart failure.

See also CPB 0709 - Nesiritide (Natrecor).


This policy is based in part upon American College of Cardiology/American Heart Association (ACC/AHA)'s 2005 Guideline Update on the Management of Chronic Heart Failure in the Adult (Hunt et al, 2005).

Plasma brain natriuretic peptide (BNP) is a 32-amino acid polypeptide that contains a 17-amino acid ring structure common to all natriuretic peptides.  The cardiac ventricles are the major source of plasma BNP.  This circulating peptide has been used as a marker to assist in the diagnosis of congestive heart failure.  In general, plasma BNP levels correlate positively with the degree of left ventricular dysfunction, but they are sensitive to other biological factors such as age, sex, and diastolic dysfunction.  Plasma BNP levels greater than 100 pg/ml are reported to support a diagnosis of abnormal or symptomatic heart failure.

The ACC/AHA practice guidelines on heart failure (Hunt et al, 2005) stated the following conclusions about the clinical utility of BNP: “Measurement of B-type natriuretic peptide (BNP) can be useful in the evaluation of patients presenting in the urgent care setting in whom the clinical diagnosis of HF is uncertain. (Level of Evidence: A).”

The guidelines stated, however, that “[t]he value of serial measurements of BNP to guide therapy for patients with HF is not well established. (Level of Evidence: C).”

The guidelines explained that serum BNP levels have been shown to parallel the clinical severity of heart failure in broad populations (Hunt et al, 2005).  Levels are higher in hospitalized patients and tend to decrease during aggressive therapy for decompensation.  The guidelines stated, however, that it can not be assumed that BNP levels can be used effectively as targets for adjustment of therapy in individual patients.  The guidelines explained that many patients taking optimal doses of medications continue to show markedly elevated levels of BNP, and some patients demonstrated BNP levels within the normal range despite advanced heart failure (HF).  The guidelines concluded that the use of BNP measurements to guide the titration of drug doses has not been shown to improve outcomes more effectively than achievement of the target doses drugs shown in clinical trials to prolong life.  The guidelines noted that ongoing trials will help to determine the role of serial BNP measurements in both diagnosis and management of heart failure.

Regarding the use of BNP to assess prognosis, the guidelines stated that elevated BNP levels predict higher risk of heart failure and other events after myocardial infarction, whereas marked elevation in BNP levels during hospitalization for heart failure may predict re-hospitalization and death (Hunt et al, 2005).  The guidelines concluded, however, that “the BNP measurement has not been clearly shown to supplement careful clinical assessment.”

Thus, measurement of plasma BNP may be medically necessary to differentiate dyspnea due to heart failure from pulmonary disease in the urgent care setting.  The value of measurements of BNP for the routine (non-urgent) diagnosis or for the management of patients with heart failure has not been established.

A 2005 technology assessment of BNP for the diagnosis and management of congestive heart failure by the Institute for Clinical Systems Improvement stated that “BNP testing is useful as an adjunct to other clinical tools for differentiating cardiac (congestive heart failure [CHF]) causes from other causes of dyspnea presenting in the emergency department or urgent care setting.”  The ICSI technology assessment stated that, in particular, the diagnosis of CHF is highly unlikely in patients with normal BNP levels.  The ICSI technology assessment states that care should be taken when measuring BNP within 2 to 4 hours after the onset of acute symptoms as false negatives may occur.  The ICSI technology assessment concluded that there are no data to support the use of BNP in the general screening of asymptomatic populations for CHF, and thus BNP testing should not be used for this purpose.  The ICSI technology assessment also concluded that the utility of BNP as a tool to optimize management of heart failure or measure treatment response has yet to be defined. “Serial testing of BNP levels has not been shown to have clinical utility” (ICSI, 2005).

In a review on the use of BNP as a potential marker of acute coronary syndromes, Body and Roberts (2006) stated that the clinical bottom line is that BNP shows promise as an early cardiac marker and may enhance prognostic stratification.  Negative-predictive value and positive-predictive value may be unacceptably low to enable use as a sole cardiac marker.  Incorporation into a multi-marker strategy and serial estimations may be necessary.

Sohne and associates (2006) determined the predictive value of elevated BNP levels for early recurrent venous thromboembolism with or without fatal outcome in hemodynamically stable patients with acute pulmonary embolism (PE).  In addition, these researchers evaluated the potential clinical consequences of initiating thrombolytic therapy based on the BNP levels alone.  A nested case-control study was performed within the framework of a large randomized-controlled trial totaling 2,213 hemodynamically stable patients with confirmed acute, symptomatic PE.  A total of 90 patients experienced a fatal or non-fatal recurrent venous thromboembolism during the first 3 months of follow-up (cases); 297 patients with uneventful follow-up served as controls.  Blood for BNP levels was obtained at referral and assayed in a central laboratory.  Cases had significantly higher mean baseline BNP levels (p = 0.0002).  The odds ratio (OR) for every logarithmic unit increase in BNP concentration was 2.4 (95 % confidence interval [CI]: 1.5 to 3.7).  A BNP cut-off level of 1.25 pmol/L [the optimal point on the receiver-operating characteristic curve] was associated with a sensitivity and specificity of 60 % and 62 %, respectively.  In theory, for every patient correctly receiving thrombolytic therapy at this cut-off, 16 patients will receive this therapy unnecessarily.  These investigators concluded that BNP level at presentation is significantly associated with early (fatal) recurrent venous thromboembolism in hemodynamically stable patients with acute PE.  However, this relationship appears clinically insufficient to guide the initiation of thrombolytic therapy.

The Agency for Healthcare Research and Quality's assessment on testing for BNP and the N-terminal fragment of B-type natriuretic peptide (NT-proBNP) in the diagnosis and prognosis of heart failure (Balion et al, 2006) stated that these natriuretic peptides can be used to rule out heart failure in patients being seen in emergency rooms, specialized clinics, and primary care settings.  It also noted that there were few studies that examined B-type natriuretic peptides in populations without known heart failure.  All but a single study suggested that measurements of these biomarkers are inaccurate to be an effective screening test for unrecognized left ventricular dysfunction.

Although several studies have addressed the use of biomarkers -- particularly BNP and NT-proBNP -- in populations with heart failure (HF), integrating these markers into clinical care has been controversial.  The National Academy of Clinical Biochemistry (NACB) convened a committee to develop practice guidelines for the use of biomarkers for screening, diagnosis, prognostication, and treatment of HF (Tang et al, 2007).  Some of the key points of this practice guideline are as follows:

  • Although natriuretic peptide levels, including longitudinal measurements, may be useful for additional risk stratification in some patients, routine use solely for HF risk stratification is discouraged (Class III recommendation).
  • Natriuretic peptide levels may be influenced by several patient factors, including age, sex, renal function, thyroid function, anemia, and body habitus.  Importantly, obese persons tend to have lower natriuretic peptide levels than do non-obese persons.
  • Natriuretic peptide levels should not replace standard clinical assessment tools, such as echocardiography (Class III recommendation)
  • Normal BNP and NT-proBNP ranges vary according to the assay used and the characteristics of the control population.  The assay commonly used for research produces systematically lower measurements than do commercial assays.
  • The committee made only one Class I recommendation for the clinical use of natriuretic peptides: to exclude or confirm the diagnosis of HF in patients with ambiguous signs and symptoms in the acute setting.  Such an application in the non-acute setting received a Class IIa recommendation for lack of studies.
  • The routine use of natriuretic peptides in the initial evaluation of patients with suspected HF, for guiding therapy in patients with established HF, and for screening purposes is also discouraged (Class III recommendations).

Thus, available data support relatively few strong recommendations for the clinical use of natriuretic peptide measurements in patients with HF, other than adjunctive use for diagnosis in the acute care setting.  Until more evidence is available on how these cardiac biomarkers should be integrated into clinical care, their routine use in the diagnosis, treatment, and screening of HF is not warranted.

Rottlaender et al (2008) stated that several factors (e.g., age, sex, obesity as well as chronic renal failure) have to be considered in the interpretation of natriuretic peptides, which may support diagnostics of HF in patients with unexplained dyspnea.  However, cardiac biomarkers should not be used to replace conventional clinical evaluation.  The use of natriuretic peptides for screening asymptomatic populations is inappropriate.  A BNP-guided titration of HF medication is not yet warranted.  Brain natriuretic peptide testing may be used only in selected situations for risk stratification since the prognostic value is still limited by a lack of clear usefulness in guiding clinical management.  The authors concluded that measurements of natriuretic peptides are at present largely an addition in the diagnosis of acute HF, as long as possible errors in interpretation are taken into account.

Mark and colleagues (2007) stated that premature cardiovascular disease is the leading cause of morbidity and mortality in patients with end-stage renal failure.  Natriuretic peptides, specifically BNP, are released from the heart in response to chamber distension and thus increased in the presence of volume expansion and cardiac overload.  Their physiological role is to cause vasodilatation and promote natriuresis to maintain volume homeostasis.  However, the diagnostic role of serum BNP levels in patients with advanced renal dysfunction remains to be defined.  This is in agreement with the observation of Rosner (2007) who noted that the diagnostic utility of BNP in end-stage renal disease is limited.

Pfisterer et al (2009) stated that it is unclear if intensified HF therapy guided by N-terminal BNP is superior to symptom-guided therapy.  In a randomized, controlled multi-center study, these investigators compared 18-month outcomes of N-terminal BNP-guided versus symptom-guided HF therapy.  A total of 499 patients aged 60 years or older with systolic HF (ejection fraction less than or equal to 45 %), New York Heart Association (NYHA) class of II or greater, prior hospitalization for HF within 1 year, and N-terminal BNP level of 2 or more times the upper limit of normal were included in this trial.  The study had an 18-month follow-up and was conducted at 15 outpatient centers in Switzerland and Germany.  Interventions were up-titration of guideline-based treatments to reduce symptoms to NYHA class of II or less (symptom-guided therapy) and BNP level of 2 times or less the upper limit of normal and symptoms to NYHA class of II or less (BNP-guided therapy).  Primary outcomes were 18-month survival free of all-cause hospitalizations and quality of life as assessed by structured validated questionnaires.  Heart failure therapy guided by N-terminal BNP and symptom-guided therapy resulted in similar rates of survival free of all-cause hospitalizations (41 % versus 40 %, respectively; hazard ratio [HR], 0.91 [95 % CI: 0.72 to 1.14]; p = 0.39).  Patients' quality-of-life metrics improved over 18 months of follow-up, but these improvements were similar in both the N-terminal BNP-guided and symptom-guided strategies.  Compared with the symptom-guided group, survival free of hospitalization for HF, a secondary end point, was higher among those in the N-terminal BNP-guided group (72 % versus 62 %, respectively; HR, 0.68 [95 % CI: 0.50 to 0.92]; p = 0.01).  Heart failure therapy guided by N-terminal BNP improved outcomes in patients aged 60 to 75 years but not in those aged 75 years or older (p < 0.02 for interaction).  The authors concluded that HF therapy guided by N-terminal BNP did not improve overall clinical outcomes or quality of life compared with symptom-guided treatment.

Schneider et al (2009) noted that BNP is used to diagnose HF, but the effects of using the test on all dyspneic patients is uncertain.  In a randomized, single-blind trial, these researchers evaluated if BNP testing alters clinical outcomes and health services use of acutely dyspneic patients.  Patients were blinded to the intervention, but clinicians and those who assessed trial outcomes were not.  A total of 612 consecutive patients who presented with acute severe dyspnea were included in this study (n = 306 for BNP testing; n = 306 for no testing).  Primary outcome measures included admission rates, length of stay, and emergency department medications; secondary outcomes were mortality and re-admission rates.  There were no between-group differences in hospital admission rates (85.6 % [BNP group] versus 86.6 % [control group]; difference, -1.0 percentage point [95 % CI: -6.5 to 4.5 percentage points]; p = 0.73), length of admission (median of 4.4 days [inter-quartile range, 2 to 9 days] versus 5.0 days [inter-quartile range of 2 to 9 days]; p = 0.94), or management of patients in the emergency department.  Test discrimination was good (area under the receiver-operating characteristic curve, 0.87 [CI: 0.83 to 0.91]).  Adverse events were not measured.  The limitations of this study were that most patients were very short of breath and required hospitalization; the findings might not apply for evaluating patients with milder degrees of breathlessness.  The authors concluded that measurement of BNP in all emergency department patients with severe shortness of breath had no apparent effects on clinical outcomes or use of health services.  It does not improve admission or discharge decisions or improve initial treatment planning.  The findings do not support routine use of BNP testing in all severely dyspneic patients in the emergency department.

Karthikeyan and colleagues (2009) performed a systematic review and meta-analysis to determine if pre-operative BNP (i.e., BNP or N-terminal pro-B-type natriuretic peptide [NT-proBNP]) is an independent predictor of 30-day adverse cardiovascular outcomes after non-cardiac surgery.  These investigators employed 5 search strategies (e.g., searching bibliographic databases), and included all studies that assessed the independent prognostic value of pre-operative BNP measurement as a predictor of cardiovascular complications after non-cardiac surgery.  These researchers determined study eligibility and conducted data abstraction independently and in duplicate.  They calculated a pooled odds ratio using a random effects model.  A total of 9 studies met eligibility criteria, and included a total of 3,281 patients, among whom 314 experienced 1 or more peri-operative cardiovascular complications.  The average proportion of patients with elevated BNP was 24.8 % (95 % CI: 20.1 % to 30.4 %; I(2) = 89 %).  All studies showed a statistically significant association between an elevated pre-operative BNP level and various cardiovascular outcomes (e.g., a composite of cardiac death and non-fatal myocardial infarction; atrial fibrillation).  Data pooled from 7 studies demonstrated an odds ratio (OR) of 19.3 (95 % CI: 8.5 to 43.7; I(2) = 58 %).  The pre-operative BNP measurement was an independent predictor of peri-operative cardiovascular events among studies that only considered the outcomes of death, cardiovascular death, or myocardial infarction (OR: 44.2, 95 % CI: 7.6 to 257.0, I(2) = 51.6 %), and those that included other outcomes (OR: 14.7, 95 % CI: 5.7 to 38.2, I(2) = 62.2 %); the p value for interaction was 0.28.  The authors concluded that these results suggested that an elevated pre-operative BNP or NT-proBNP measurement is a powerful, independent predictor of cardiovascular events in the first 30 days after non-cardiac surgery.

In an editorial that accompanied the afore-mentioned paper, Bolliger et al (2009) stated that the study by Karthikeyan et al provided evidence for a high prognostic potential of NPs in patients scheduled for non-cardiac surgery.  However, studies to evaluate if specific NP-based treatment modifications will result in improved outcome of surgical patients still need to be performed.  Should future studies find outcome relevance of such a concept, NPs will be indeed the magic bullet of pre-operative risk optimization.  So far, however, they are interesting and promising tools for risk stratification that requires further evaluation.

Cleland et al (2009) examined if plasma NT-proBNP a marker of cardiac dysfunction and prognosis measured in CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure) could be used to identify the severity of HF at which statins become ineffective.  In CORONA, patients with HF, reduced left ventricular ejection fraction, and ischemic heart disease were randomly assigned to 10 mg/day rosuvastatin or placebo.  The primary composite outcome was cardiovascular death, non-fatal myocardial infarction, or stroke.  Of 5,011 patients enrolled, NT-proBNP was measured in 3,664 (73 %).  The mid-tertile included values between 103 pmol/L (868 pg/ml) and 277 pmol/L (2,348 pg/ml).  Log NT-proBNP was the strongest predictor (per log unit) of every outcome assessed but was strongest for death from worsening HF (HR: 1.99; 95 % CI: 1.71 to 2.30), was weaker for sudden death (HR: 1.69; 95 % CI: 1.52 to 1.88), and was weakest for athero-thrombotic events (HR: 1.24; 95 % CI: 1.10 to 1.40).  Patients in the lowest tertile of NT-proBNP had the best prognosis and, if assigned to rosuvastatin rather than placebo, had a greater reduction in the primary end point (HR: 0.65; 95 % CI: 0.47 to 0.88) than patients in the other tertiles (heterogeneity test, p = 0.0192).  This reflected fewer athero-thrombotic events and sudden deaths with rosuvastatin.  The authors concluded that patients with HF due to ischemic heart disease who have NT-proBNP values less than 103 pmol/l (868 pg/ml) may benefit from rosuvastatin.

In an editorial that accompanied the study by Cleland et al, Daniels and Barrett-Connor (2009) stated that clinical practice guidelines recommend that statins be prescribed to patients with ischemic heart disease, but do not make HF a consideration.  If these findings are confirmed in other studies, NP levels may have a new application in guiding statin decisions for HF patients.

In a meta-analysis, Porapakkham and associates (2010) examined the overall effect of BNP-guided drug therapy on cardiovascular outcomes in patients with chronic HF.  These researchers identified randomized controlled trials (RCTs) by systematic search of manuscripts, abstracts, and databases.  Eligible RCTs were those that enrolled more than 20 patients and involved comparison of BNP-guided drug therapy versus usual clinical care of the patient with chronic HF in an out-patient setting.  Eight RCTs with a total of 1,726 patients and with a mean duration of 16 months (range of 3 to 24 months) were included in the meta-analysis.  Overall, there was a significantly lower risk of all-cause mortality (relative risk [RR], 0.76; 95 % CI: 0.63 to 0.91; p = 0.003) in the BNP-guided therapy group compared with the control group.  In the subgroup of patients younger than 75 years, all-cause mortality was also significantly lower in the BNP-guided group (RR, 0.52; 95 % CI: 0.33 to 0.82; p = 0.005).  However, there was no reduction in mortality with BNP-guided therapy in patients 75 years or older (RR, 0.94; 95 % CI: 0.71 to 1.25; p = 0.70).  The risk of all-cause hospitalization and survival free of any hospitalization was not significantly different between groups (RR, 0.82; 95 % CI: 0.64 to 1.05; p = 0.12 and RR, 1.07; 95 % CI: 0.85 to 1.34; p = 0.58, respectively).  The additional percentage of patients achieving target doses of angiotensin-converting enzyme inhibitors and beta-blockers during the course of these trials averaged 21 % and 22 % in the BNP group and 11.7 % and 12.5 % in the control group, respectively.  The authors concluded that B-type natriuretic peptide-guided therapy reduces all-cause mortality in patients with chronic HF compared with usual clinical care, especially in patients younger than 75 years.  A component of this survival benefit may be due to increased use of agents proven to decrease mortality in chronic HF.  However, there does not seem to be a reduction in all-cause hospitalization or an increase in survival free of hospitalization using this approach.

Eurlings et al (2010) examined if management of HF guided by an individualized NT-proBNP target would lead to improved outcome compared with HF management guided by clinical assessment alone.  A total of 345 patients hospitalized for decompensated, symptomatic HF with elevated NT-proBNP levels at admission were included.  After discharge, patients were randomized to either clinically-guided outpatient management (n = 171), or management guided by an individually set NT-proBNP (n = 174) defined by the lowest level at discharge or 2 weeks thereafter.  The primary end point was defined as number of days alive outside the hospital after index admission.  Management of HF guided by this individualized NT-proBNP target increased the use of HF medication (p = 0.006), and 64 % of HF-related events were preceded by an increase in NT-proBNP.  Nevertheless, HF management guided by this individualized NT-proBNP target did not significantly improve the primary end point (685 versus 664 days, p = 0.49), nor did it significantly improve any of the secondary end points.  In the NT-proBNP-guided group mortality was lower, as 46 patients died (26.5 %) versus 57 (33.3 %) in the clinically-guided group, but this was not statistically significant (p = 0.206).  The authors concluded that serial NT-proBNP measurement and targeting to an individual NT-proBNP value did result in advanced detection of HF-related events and importantly influenced HF-therapy, but failed to provide significant clinical improvement in terms of mortality and morbidity. 

In an editorial that accompanied the afore-mentioned study by Eurlings et al, Troughton et al (2010) stated that "further data are needed from more robust, adequately powered trials with hard clinical outcomes and from a meta-analysis utilizing individual patient data (rather than summary grouped data) before guidelines can confidently endorse a biomarker-guided strategy ... Whether the biomarker-guided strategy is applicable to elderly patients and those with heart failure and preserved left ventricular ejection fraction remains unclear and needs further evaluation".  Furthermore, Kim and Januzzi (2011) noted that "although evidence is increasing that NP-guided outpatient management of HF may improve clinical outcomes, more information is needed before adoption of such an approach, which is currently being tested in clinical trials".

Previous studies reported that plasma NT-proBNP has prognostic value for cardiovascular events in the general population even in the absence of HF.  It is unclear if NT-proBNP retains predictive value in healthy normal subjects.  McKie and associates (2010) determined the prognostic value of plasma NT-proBNP for death and cardiovascular events among subjects without risk factors for HF, which the authors termed healthy normal.  These investigators identified a community-based cohort of 2,042 subjects in Olmsted County, Minnesota.  Subjects with symptomatic (stage C/D) HF were excluded.  The remaining 1,991 subjects underwent echocardiography and NT-proBNP measurement.  These researchers further defined healthy normal (n = 703) and stage A/B HF (n = 1,288) subgroups.  Healthy normal was defined as the absence of traditional clinical cardiovascular risk factors and echocardiographic structural cardiac abnormalities.  Subjects were followed for death, HF, cerebrovascular accident, and myocardial infarction with median follow-up of 9.1, 8.7, 8.8, and 8.9 years, respectively.  NT-proBNP was not predictive of death or cardiovascular events in the healthy normal subgroup.  Similar to previous reports, in stage A/B HF, plasma NT-proBNP values greater than age-/sex-specific 80th percentiles were associated with increased risk of death, HF, cerebrovascular accident, and myocardial infarction (p < 0.001 for all) even after adjustment for clinical risk factors and structural cardiac abnormalities.  The authors concluded that these findings do not support the use of NT-proBNP as a cardiovascular biomarker in healthy normal subjects.

Nadir and colleagues (2011) noted that studies in victims of sudden cardiac death and those surviving a cardiac arrest have confirmed that extent of coronary artery disease is similar in those with and without angina, suggesting that it is the presence of myocardial ischemia rather than associated symptoms that determine the prognosis. Experimental models show that hypoxic myocardial tissue results in production of extra BNP, suggesting that BNP could potentially serve as a biomarker of myocardial ischemia.  These investigators performed a meta-analysis of the studies that link BNP to inducible myocardial ischemia as indicated by non-invasive stress tests.  Values of true-positive, false-positive, true-negative, and false-negative were calculated from the reported sensitivity, specificity, disease prevalence, and total number of patients studied.  A total of 16 studies reporting data on 2,784 patients across 14 study populations were included in the final analysis.  Mean age of participants was 55 to 69 years and 55 % to 90 % were men.  Pooled sensitivity and specificity of BNP for detection of stress-induced myocardial ischemia were 71 % (95 % CI: 68 to 74) and 52 % (95 % CI: 52 to 54), respectively.  Pooled diagnostic odds ratio was 3.5 (95 % CI: 2.46 to 5.04) and summary receiver operating characteristic curve revealed an area under the curve of 0.71 +/- 0.02 (mean +/- SE).  The authors concluded that this meta-analysis suggests that an increased BNP level can identify inducible ischemia as detected by standard non-invasive stress tests.  They stated that this raises the possibility of a whole new role for BNP in the diagnosis and management of myocardial ischemia.

Pfister et al (2011) noted that genetic and epidemiological evidence suggests an inverse association between BNP levels in blood and risk of type 2 diabetes (T2D), but the prospective association of BNP with T2D is uncertain, and it is unclear whether the association is confounded.  In a prospective, case-cohort study, these researchers analysed the association between levels of the NT-proBNP in blood and risk of incident T2D and genotyped the variant rs198389 within the BNP locus in 3 T2D case-control studies.  They combined their results with existing data in a meta-analysis of 11 case-control studies.  Using a Mendelian randomization approach, these investigators compared the observed association between rs198389 and T2D to that expected from the NT-proBNP level to T2D association and the NT-proBNP difference per C allele of rs198389.  In participants of this case-cohort study who were free of T2D and cardiovascular disease at baseline, these researchers observed a 21 % (95 % CI: 3 % to 36 %) decreased risk of incident T2D per 1 standard deviation (SD) higher log-transformed NT-proBNP levels in analysis adjusted for age, sex, body mass index, systolic blood pressure, smoking, family history of T2D, history of hypertension, and levels of triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol.  The association between rs198389 and T2D observed in case-control studies (odds ratio= 0.94 per C allele, 95 % CI: 0.91 to 0.97) was similar to that expected (0.96: 0.93 to 0.98) based on the pooled estimate for the log-NT-proBNP level to T2D association derived from a meta-analysis of the authors' study and published data (hazard ratio = 0.82 per SD, 0.74 to 0.90) and the difference in NT-proBNP levels (0.22 SD, 0.15 to 0.29) per C allele of rs198389.  No significant associations were observed between the rs198389 genotype and potential confounders.  The authors concluded that these findings provided evidence for a potential causal role of the BNP system in the etiology of T2D.  They stated that further studies are needed to investigate the mechanisms underlying this association and possibilities for preventive interventions.

In a single-center, retrospective study, Takatsuki et al (2012) examined if NT-proBNP was a biomarker of clinical, laboratory, and echocardiographic abnormalities in children with homozygous sickle cell disease.  This study consisted of analysis of data from November 2007 to December 2010.  These investigators correlated serum NT-proBNP with clinical and laboratory findings, echocardiographic data, and NYHA functional class.  NT-proBNP levels from 42 children (median age of 9 years; 52 % female) had significant correlations with hemoglobin (r = -0.63, p < 0.05), and echocardiographic measurements including tricuspid regurgitant velocity (r = 0.46, p < 0.05), lateral E' (r = -0.52, p < 0.05), and lateral E/E' ratio (an indicator of left ventricular filling pressures and is used in the assessment of diastolic dysfunction)  (r = 0.60, p < 0.05), suggesting diastolic dysfunction.  In addition, NT-proBNP levels increased from NYHA functional class I to class III and had a significant linear correlation with the NYHA functional class (r = 0.69, p < 0.05).  The authors concluded that NT-proBNP correlated with low hemoglobin and tissue Doppler data as indicators of diastolic dysfunction.  Elevated NT-proBNP may be a prognostic biomarker for the presence of diastolic dysfunction related to anemia in children with sickle cell disease.  The findings of this small, retrospective study need to be validated by well-designed studies.

Lin and colleagues (2012) noted that novel biomarkers of myocardial ischemia and inflammatory processes have the potential to improve diagnostic accuracy of acute coronary syndrome (ACS) within a shorter time interval after symptom onset.  These researchers reviewed the recent literature and evaluated the evidence for use of novel biomarkers in diagnosing ACS in patients presenting with chest pain or symptoms suggestive of cardiac ischemia to the emergency department or chest pain unit.  A literature search was performed in MEDLINE, EMBASE, Cochrane DSR, ACP Journal Club, DARE, CCTR, CMR, HTA, and NHSEED for studies from 2004 to 2010.  They used the inclusion criteria: (i) human subjects, (ii) peer-reviewed articles, (iii) enrolled patients with ACS, acute myocardial infarction or undifferentiated signs and symptoms suggestive of ACS, and (iv) English language or translated manuscripts.  Two reviewers conducted a hierarchical selection and assessment using a scale developed by the International Liaison Committee on Resuscitation.  Out of a total 3,194 citations, 58 articles evaluating 37 novel biomarkers were included for final review.  A total of 41 studies did not support the use of their respective biomarkers; 17 studies supported the use of 5 biomarkers, particularly when combined with cardiac-specific troponin: heart fatty acid-binding protein, ischemia-modified albumin, B-type natriuretic peptide, copeptin, and matrix metalloproteinase-9.  The authors concluded that in patients presenting to the emergency department with chest pain or symptoms suggestive of cardiac ischemia, there is inadequate evidence to suggest the routine testing of novel biomarkers in isolation.  Moreover, they stated that several novel biomarkers have the potential to improve the sensitivity of diagnosing ACS when combined with cardiac-specific troponin.

Eindhoven et al (2012) stated that BNP and NT-proBNP are well-established markers for heart failure in the general population.  However, the value of BNP as a diagnostic and prognostic marker for patients with structural congenital heart disease (CHD) is still unclear.  These investigators evaluated the clinical utility of BNP in patients with CHD.  They executed a PubMed literature search and included 49 articles that focused on complex congenital heart defects such as tetralogy of Fallot, systemic right ventricle, and uni-ventricular hearts.  Data on BNP measurements and cardiac function parameters were extracted.  In all patients after correction for tetralogy of Fallot, BNP levels were elevated and correlated significantly with right ventricular end-diastolic dimensions and severity of pulmonary valve regurgitation.  Patients with a systemic right ventricle had elevated BNP levels, and positive correlations between BNP and right ventricular function were seen.  In patients with a uni-ventricular heart, elevated BNP levels were observed before completion of the Fontan circulation or when patients were symptomatic; a clear association between BNP and NYHA functional class was demonstrated.  The authors concluded that this review showed an overall increase in BNP values in complex CHD, although differences between types of congenital heart anomaly are present.  As BNP values differ widely, conclusions for individual patients should be drawn with caution.  They stated that further investigation with sequential BNP measurement in a large, prospective study is warranted to elucidate the prognostic value of BNP assessment in patients with CHD.

Eindhoven et al (2014) determined the value of NT-proBNP in adults with ToF and established its relationship with echocardiography and exercise capacity.  Electrocardiography, detailed 2D-echocardiography and NT-proBNP measurement were performed on the same day in 177 consecutive adults with ToF (mean age of 34.6 ± 11.8 years, 58 % male, 89 % NYHA I, 29.3 ± 8.5years after surgical correction); 38 % of the patients also underwent a cardiopulmonary-exercise test.  Median NT-proBNP was 16 [IQR 6.7 to 33.6] pmol/L, and was elevated in 55 %.  NT-proBNP correlated with right ventricular (RV) dilatation (r = 0.271, p < 0.001) and RV systolic dysfunction (r = -0.195, p = 0.022), but more strongly with LV systolic dysfunction (r = -0.367, p < 0.001), which was present in 69 patients (39 %).  Moderate or severe pulmonary regurgitation was not associated with higher NT-proBNP.  Tricuspid and pulmonary regurgitation peak velocities correlated with NT-proBNP (r = 0.305, p < 0.001 and r = 0.186, p = 0.045, respectively).  Left ventricular twist was measured with speckle-tracking echocardiography in 71 patients.  An abnormal LV twist (20 patients, 28 %) was associated with elevated NT-proBNP (p = 0.030).  No relationship between NT-proBNP and exercise capacity was found.  The authors concluded that NT-proBNP levels were elevated in more than 50 % of adults with corrected ToF, while they were in stable clinical condition.  Higher NT-proBNP is most strongly associated with elevated pulmonary pressures, and with LV dysfunction rather than RV dysfunction.  They stated that NT-proBNP has the potential to become routine examination in patients with ToF to monitor ventricular function and may be used for timely detection of clinical deterioration.

García-Berrocoso et al (2013) measured the association of BNP and NT-proBNP with all-cause mortality after stroke, and evaluated the additional predictive value of BNP/NT-proBNP over clinical information.  Suitable studies for meta-analysis were found by searching MEDLINE and EMBASE databases until October 26, 2012.  Weighted mean differences measured effect size; meta-regression and publication bias were assessed.  Individual participant data were used to estimate effects by logistic regression and to evaluate BNP/NT-proBNP additional predictive value by area under the receiver operating characteristic curves, and integrated discrimination improvement and categorical net re-classification improvement indexes.  Literature-based meta-analysis included 3,498 stroke patients from 16 studies and revealed that BNP/NT-proBNP levels were 255.78 pg/ml (95 % CI: 105.10 to 406.47, p = 0.001) higher in patients who died; publication bias entailed the loss of this association.  Individual participant data analysis comprised 2,258 stroke patients.  After normalization of the data, patients in the highest quartile had doubled the risk of death after adjustment for clinical variables (NIH Stroke Scale score, age, sex) (odds ratio 2.30, 95 % CI: 1.32 to 4.01 for BNP; and odds ratio 2.63, 95 % CI: 1.75 to 3.94 for NT-proBNP).  Only NT-proBNP showed a slight added value to clinical prognostic variables, increasing discrimination by 0.028 points (integrated discrimination improvement index; p < 0.001) and reclassifying 8.1 % of patients into correct risk mortality categories (net re-classification improvement index; p = 0.003).  Neither etiology nor time from onset to death affected the association of BNP/NT-proBNP with mortality.  The authors concluded that BNPs are associated with post-stroke mortality independent of NIH Stroke Scale score, age, and sex.  However, their translation to clinical practice seems difficult because BNP/NT-proBNP add only minor predictive value to clinical information.  Thus, although this association was statistically significant, these biomarkers did not lead to better prediction of death than clinical information alone.

Hijazi et al (2013) assessed the prognostic value of NT-proBNP in patients with atrial fibrillation (AF) enrolled in the ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation) trial, and the treatment effect of apixaban according to NT-proBNP levels.  In the ARISTOTLE trial, 18,201 patients with AF were randomized to apixaban or warfarin.  Plasma samples at randomization were available from 14,892 patients.  The association between NT-proBNP concentrations and clinical outcomes was evaluated using Cox proportional hazard models, after adjusting for established cardiovascular risk factors.  Quartiles of NT-proBNP were: Q1, less than or equal to 363 ng/L; Q2, 364 to 713 ng/L; Q3, 714 to 1,250 ng/L; and Q4, greater than 1,250 ng/L.  During 1.9 years, the annual rates of stroke or systemic embolism ranged from 0.74 % in the bottom NT-proBNP quartile to 2.21 % in the top quartile, an adjusted HR of 2.35 (95 % CI: 1.62 to 3.40; p < 0.0001).  Annual rates of cardiac death ranged from 0.86 % in Q1 to 4.14 % in Q4, with an adjusted HR of 2.50 (95 % CI: 1.81 to 3.45; p < 0.0001).  Adding NT-proBNP levels to the CHA2DS2VASc score improved C-statistics from 0.62 to 0.65 (p = 0.0009) for stroke or systemic embolism and from 0.59 to 0.69 for cardiac death (p < 0.0001).  Apixaban reduced stroke, mortality, and bleeding regardless of the NT-proBNP level.  The authors concluded that NT-proBNP levels are often elevated in AF and independently associated with an increased risk of stroke and mortality.  They stated that NT-proBNP improved risk stratification beyond the CHA2DS2VASc score and might be a novel tool for improved stroke prediction in AF.  The effectiveness of apixaban compared with warfarin is independent of the NT-proBNP level.

In a prospective study, Rodriguez-Yanez et al (2013) examined if pro-BNP levels in the acute phase of stroke predict the development of AF in patients with cryptogenic stroke.  Demographic data, medical history, and stroke characteristics were assessed at admission.  A blood sample was obtained within the first 24 hours from stroke onset to determine pro-BNP levels.  Patients were followed by a neurologist at 3 and 6 months and later by a primary care physician for 2 years to evaluate the development of AF.  A total of 1,050 patients with ischemic stroke were evaluated -- 372 patients (35 %) had cryptogenic stroke.  A total of 108 patients were excluded from the study, so 264 patients were valid for the analysis.  Atrial fibrillation was detected in 15 patients (5.6 %) during the follow-up.  Patients who developed AF were older, had hypertension more frequently, and showed higher levels of pro-BNP.  In the logistic regression model, these researchers found that pro-BNP greater than or equal to 360 pg/ml was the only variable independently associated with the risk of developing AF (OR 5.70, 95 % CI: 1.11 to 29.29, p = 0.037).  The authors concluded that pro-BNP greater than or equal to 360 pg/ml increases by 5-fold the possibility of detecting AF during follow-up in patients with cryptogenic stroke.  They stated that pro-BNP levels of greater than or equal to 360 pg/ml determine during the acute phase of cryptogenic stroke may be useful to identify patients at risk of AF during the 2 years after the stroke.  The drawbacks of this study included (i) there were no data regarding the left atrial size of left ventricular ejection fraction, which are independent risk factor for AF development, (ii) there was no information about treatment before admission that could affect pro-BNP levels, and (iii) these researchers did not examine the temporal profile of pro-BNP, and some studies found that pro-BNP levels decrease in the days following a stroke. 

Roldan et al (2014) stated that oral anti-coagulation is highly effective in reducing stroke and mortality in AF.  Several risk stratification schemes have been developed using clinical characteristics.  Elevated levels of NT-proBNP are important markers of increased mortality and morbidity in CHF and general community population.  These investigators evaluated the predictive value of NT-proBNP levels in an unselected real-world cohort of anti-coagulated patients with AF.  These researchers studied 1,172 patients (49 % male; median age of 76 years) with permanent AF who were well-stabilized on oral anti-coagulation (international normalized ratio, 2.0 to 3.0).  Plasma NT-proBNP levels were quantified at baseline.  These researchers recorded thrombotic and vascular events, mortality, and major bleeding.  The best cut-off points were assessed by receiver-operating characteristic curves.  Median levels (interquartile range) of NT-proBNP were 610 (318 to 1,037) pg/ml.  Median follow-up was 1,007 (806 to 1,279) days.  On multi-variate analysis, high NT-proBNP was significantly associated with the risk of stroke (HR, 2.71; p = 0.001) and composite vascular events (acute coronary syndrome or acute heart failure; HR, 1.85; p = 0.016), as well as a significant association with mortality (adjusted HR, 1.66; p = 0.006).  No association with bleeding was found (p = 0.637).  The integrated discrimination improvement (IDI) analysis demonstrated that NT-proBNP improved the CHF, Hypertension, Age greater than or equal to 75 (doubled), Diabetes mellitus, Stroke (doubled)-Vascular disease and Sex category (female); CHA2DS2-VASc score for predicting embolic events (relative IDI, 2.8 %; p = 0.001) and all-cause death (relative IDI, 1.8 %; p = 0.001).  The authors concluded that in real-world cohort of anti-coagulated patients with AF, NT-proBNP provided complementary prognostic information to an established clinical risk score (CHA2DS2-VASc) for the prediction of stroke/systemic embolism.  Moreover, they stated that NT-proBNP was also predictive of all-cause mortality, suggesting that this biomarker may potentially be used to refine clinical risk stratification in anti-coagulated patients with AF.

Balion et al (2014) stated that BNP/NT-proBNP measurement has not gained widespread use for the management of patients with HF despite several RCTs.  These investigators performed a systematic review addressing the question of whether patients with HF benefit from BNP-assisted therapy or intensified therapy compared with usual care.  Relevant RCTs were selected by searching Medline, Embase, AMED, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and CINAHL for English-language articles published from 1980 to 2012.  Selected studies required patients to be treated for chronic HF with medical therapy based on BNP/NT-proBNP or usual care.  There were no restrictions except that BNP/NT-proBNP measurement had to be done by an FDA-approved method.  A total of 9 RCTs were identified with 2,104 patients with study duration that ranged from 3 to 18 months.  Overall, there was a wide variation in study design and how parameters were reported including patient selection, baseline characteristics, therapy goals, BNP/NT-proBNP cut-point, and outcome types.  Meta-analysis was not appropriate given this study heterogeneity.  The strength of evidence for the outcome of mortality, reported in 7 studies, was found to be low due to inconsistency and imprecision.  The authors concluded that the findings of this systematic review showed that the evidence is of low quality and insufficient to support the use of BNP/NT-proBNP to guide HF therapy.  They stated that further trials with improved design are needed.

Diagnosis of Cardio-Embolic Stroke:

Yang et al (2014) performed a systematic review and meta-analysis to evaluate the value of BNP in differentiating cardio-embolic (CE) stroke from other subtypes of ischemic stroke.  These investigators searched the EMBASE, MEDLINE, and Cochrane databases and reference lists of relevant articles published in April 2013.  They selected original studies reporting the performance of BNP or NT-proBNP in diagnosing CE stroke and summarized test performance characteristics using forest plots, hierarchical summary receiver operating characteristic curves, and bivariate random-effect models.  Data from 2,958 patients with ischemic stroke were retrieved from 16 studies.  Of these, 1,024 (34.6 %) patients had a final diagnosis of CE stroke.  Overall, the mean diagnostic OR (DOR) of BNP for CE stroke was 15.8 (95 % CI: 9.92 to 25.20).  Even after adjustment for multiple clinical predictors, serum natriuretic peptide levels showed a strong association with CE stroke (pooled adjusted DOR, 12.7; 95 % CI: 7.32 to 22.0).  The sensitivity and specificity of BNP for CE stroke were 0.78 (95 % CI: 0.71 to 0.87) and 0.83 (95 % CI: 0.77 to 0.87), respectively.  A single BNP-negative result may be sufficient to exclude a diagnosis of CE stroke in low-prevalence (less than 20 %) settings.  Subgroup analysis showed that NT-proBNP had a slightly higher specificity (0.87; 95 % CI: 0.77 to 0.93) and better capability for exclusion diagnosis.  There was a lack of homogeneity in the timing of measurement and BNP assay method.  The authors concluded that BNP has reasonable accuracy in the diagnosis of CE stroke and may be a useful marker for the early detection in patients who may benefit from preventive anti-coagulation therapy.

An UpToDate review on “Clinical diagnosis of stroke subtypes” (Caplan, 2015a) does not mention the use of measurement of plasma brain natriuretic peptide as a diagnostic tool.  Furthermore, an UpToDate review on “Overview of the evaluation of stroke” (Caplan, 2015b) states that “Other potential indicators that may predict which patients have or are likely to develop atrial fibrillation include determination of the left atrial appendage ejection fraction by transesophageal echocardiography and demonstration of an atrial fibrillation phenotype on left atrial appendage pulse wave Doppler even when the surface ECG shows normal sinus rhythm.  In addition, measurements of B-type (brain) natriuretic protein (BNP) and the N-terminal fragment of BNP indicate that these values are elevated in patients with atrial fibrillation who have cardiogenic embolism, even in those with normal ventricular function, when compared with patients who have non-cardiogenic stroke.  These measurements in patients with normal cardiac ventricular function might identify those who have intermittent atrial fibrillation or are prone to develop it.  Further research is needed to confirm whether these indicators are clinically useful”

Diagnosis of Patent Ductus Arteriosus:

Farombi-Oghuvbu et al (2008) noted that BNP is a marker for ventricular dysfunction secreted as a pre-prohormone, proBNP, and cleaved into BNP and a biologically inactive fragment, NT-proBNP.  Little is known about the clinical usefulness of NT-proBNP in preterm infants.  These researchers evaluated the usefulness of plasma NT-proBNP in diagnosing hemodynamically significant patent ductus arteriosus (hsPDA) in neonates and examined some factors that might affect this.  Infants born at less than 34 weeks' gestational age (GA) and less than 2 kg birth weight (BW) were prospectively enrolled within 6 to 12 hours of birth.  Plasma NT-proBNP levels were measured on days 1, 3, 5 and 10 with simultaneous echocardiography done to detect hsPDA and assess ventricular function.  Significant PDA was diagnosed by large ductal flow with left to right shunt on color Doppler, measuring greater than 1.6 mm on 2-dimensional echocardiography, along with clinical features of PDA.  A total of 49 infants were analyzed.  Median GA was 30 weeks (range of 24 to 33) and median BW 1,220 g (range of 550 to 1,950).  Eighteen infants with hsPDA had higher day 3 plasma NT-proBNP values (median of 32,907 pg/ml; range of 11,396 to 127,155) (p < 0.001) than controls (median of 3,147 pg/ml; range of 521 to 10,343).  Infants who developed sepsis had higher day 10 plasma NT-proBNP levels.  Area under receiver operator characteristic curve for detection of hsPDA, by day 3 NT-proBNP value, was significant 0.978 (95 % CI: 0.930 to 1.026).  NT-proBNP was predictive of hsPDA (sensitivity 100 %; specificity 95 %) at a cut-off value of 11,395 pg/ml.  The authors concluded that plasma NT-proBNP level on day 3 is a good marker for hsPDA in preterm infants; serial measurements of NT-proBNP may be useful in assessing the clinical course of PDA.

Kulkarni et al (2015) stated that echocardiogram is the gold standard for the diagnosis of hsPDA in preterm neonates.  A simple blood assay BNP or NT-proBNP may be useful in the diagnosis and management of hsPDA.  These researchers determined the diagnostic accuracy of BNP and NT-proBNP for hsPDA in preterm neonates and explored heterogeneity by analyzing subgroups.  The systematic review was performed as recommended by the Cochrane Diagnostic Test Accuracy Working Group.  Electronic databases, conference abstracts, and cross-references were searched.  These investigators included studies that evaluated BNP or NT-proBNP (index test) in preterm neonates with suspected hsPDA (participants) in comparison with echocardiogram (reference standard).  A bivariate random effects model was used for meta-analysis, and summary receiver operating characteristic curves were generated.  A total of 10 BNP and 11 NT-proBNP studies were included.  Studies varied by methodological quality, type of commercial assay, thresholds, age at testing, gestational age, and whether the assay was used to initiate medical or surgical therapy.  Sensitivity and specificity for BNP at summary point were 88 % and 92 %, respectively, and for NT-proBNP they were 90 % and 84 %, respectively.  The authors concluded that studies evaluating the diagnostic accuracy of BNP and NT-proBNP for hsPDA varied widely by assay characteristics (assay kit and threshold) and patient characteristics (gestational and chronological age); therefore, generalizability between centers is not possible.  They recommended that BNP or NT-proBNP assays be locally validated for specific patient population and outcomes, to initiate therapy or follow response to therapy.

Furthermore, an UpToDate reviews on “Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants” (Phillips, 2015) states that “Biomarkers, especially B-type natriuretic peptide (BNP) or the inactive N-terminal pro-BNP, which has a longer half-life, have been proposed as useful in the diagnosis and management of PDA.  However, the sensitivity and specificity of these tests vary in different populations and sites and further study is needed to identify their role in the diagnosis of PDA”.

CPT Codes / HCPCS Codes / ICD-10 Codes
Information in the [brackets] below has been added for clarification purposes.   Codes requiring a 7th character are represented by "+":
ICD-10 codes will become effective as of October 1, 2015:
CPT codes covered if selection criteria are met:
83880 Natriuretic peptide [except as a cardiovascular biomarker in healthy normal subjects and for identifying stress-induced myocardial ischemia]
ICD-10 codes covered if selection criteria are met:
I50.1 - I50.9 Heart failure [not covered for titrating therapy for members with chronic heart failure or monitoring the effectiveness of therapy for members with congestive heart failure or determining prognosis of members with chronic heart failure or screening unrecognized left ventricular dysfunction]
J40 - J47.9 Chronic lower respiratpru doseases
R06.00 - R06.09 Dyspnea [not covered for routine evaluation of dyspnea, other than where necessary to distinguish heart failure from pulmonary disease]
R06.82 Tachypnea, not elsewhere classified [not covered for routine evaluation of dyspnea, other than where necessary to distinguish heart failure from pulmonary disease]
ICD-10 codes not covered for indications listed in the CPB:
D57.0 - D57.819 Sickle-cell disorders [sickle-cell anemia]
E11.00 - E13.9 Diabetes Mellitus, type II
G45.0 - G45.9 Transient cerebral ischemic attacks and related syndromes
I12.0 - I12.9 Hypertensive chronic kidney disease [not covered for managing (diagnostic, prognostic and therapeutic) members with chronic renal failure]
I13.0 - I13.2 Hypertensive heart and chronic kidney disease [not covered for managing (diagnostic, prognostic and therapeutic) members with chronic renal failure]
I20.0 - I25.9 Ischemic heart diseases [not covered for identification of stress-induced myocardial ischemia][including cardio-embolic stroke]
I26.01 - I28.9 Pulmonary heart disease and diseases of pulmonary circulation [not covered for guiding the initiation of thrombolytic therapy in members with acute pulmonary embolism]
I48.0 - I48.2 Atrial fibrillation [not covered for prediction of atrial fibrillation after cryptogenic stroke]
I51.0 - I51.9 Complications and ill-defined descriptions of heart disease [not covered for screening unrecognized left ventricular dysfunction]
I65.01 - I67.9 Occlusion and stenosis of precerebral and cerebral arteries and transient cerebral ischemia [stroke or transient ischemic attack of obscure or unknown origin] [not covered for prediction of fatal outcome after stroke][including cardio-embolic stroke]
J86.0 - J86.9 Pyothorax [not covered for guiding the initiation of thrombolytic therapy in members with acute pulmonary embolism]
N18.1 - N18.9 Chronic kidney disease (CKD) [not covered for managing (diagnostic, prognostic and therapeutic) members with chronic renal failure]
Q20.0 - Q28.9 Congenital malformations of the circulatory system [not covered for detection of early cardiac dysfunction in individuals with tetralogy of Fallot]
Z01.810 Encounter for preprocedural cardiovascular examination [pre-operative cardiac risk assessment in non-cardiac surgery]
Z13.6 Encounter for screening for cardiovascular disorders [pre-operative cardiac risk assessment in non-cardiac surgery]

The above policy is based on the following references:
    1. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Bethesda, MD: American College of Cardiology; 2001. Available at: Accessed April 26, 2002.
    2. Biosite Diagnostics. Triage BNP Test to Aid in the Diagnosis of CHF. San Diego, CA: Biosite; 2001.
    3. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 2001;37(2):379-385.
    4. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: A pilot study. J Am Coll Cardiol. 2001;37(2):386-391.
    5. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345(14):1014-1021.
    6. Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: A pilot study. J Cardiac Failure. 2001;7(1):21-29.
    7. Silver MA. Are you ready for another paradigm shift? [editorial]. Congest Heart Failure. 2001;7:242-243.
    8. Grant A, Uber PA, Myung HP, et al. Novel diagnostic markers in heart failure: An emerging paradigm shift? Congest Heart Failure. 2001;7:274-276.
    9. Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001;141(3):367-374.
    10. Maisel AS. B-type natriuretic peptide (BNP) levels: Diagnostic and therapeutic potential. Rev Cardiovasc Med. 2001(2 Suppl 2):S13-S18.
    11. Lozano P. Natriuretic peptides. J Ark Med Soc. 2002;99(1):19-21.
    12. Cowie MR, Mendez GF. BNP and congestive heart failure. Prog Cardiovasc Dis. 2002;44(4):293-321.
    13. Peacock WF 4th. The B-type natriuretic peptide assay: A rapid test for heart failure. Cleve Clin J Med. 2002;69(3):243-251.
    14. Wu AH, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail. 2004;6(3):355-358.
    15. Richards M, Troughton RW. NT-proBNP in heart failure: Therapy decisions and monitoring. Eur J Heart Fail. 2004;6(3):351-354.
    16. de Denus S, Pharand C, Williamson DR. Brain natriuretic peptide in the management of heart failure: The versatile neurohormone. Chest. 2004;125(2):652-668.
    17. Mundy L, Merlin T, Bywood P, Parrella A. Elecsys ProBNP immunoassay for the diagnosis of congestive heart failure. Horizon Scanning Prioritising Summary - Volume 4. Adelaide, SA: Adelaide Health Technology Assessment (AHTA) on behalf of National Horizon Scanning Unit (HealthPACT and MSAC); 2004.
    18. Alberta Heritage Foundation for Medical Research (AHFMR). B-type natriuretic peptide for diagnosing congestive heart failure. TechNote. TN 46. Edmonton, AB: AHFMR; July 2004.
    19. Institute for Clinical Systems Improvement (ICSI). B-type natriuretic peptide (BNP) for the diagnosis and management of congestive heart failure. ICSI Technology Assessment. TA# 091. Bloomington, MN: ICSI; August 2005. Availableat: Accessed September 22, 2005.
    20. Swedish Council on Technology Assessment in Health Care (SBU). Natriuretic peptides in diagnosing heart failure -- early assessment briefs (Alert). SBU Alert Report No: 2005-01. Stockholm, Sweden: SBU; January 21, 2005.
    21. Van Brabandt H, Van den Steen D, Cleemput I. Natriuretic peptides in the diagnostic work-up of patients with suspected heart failure. KCE Reports Vol. 24B. Ref. D/2005/10.273/35. Brussels, Belgium; KCE; 2005.
    22. Anderson C, Jacobs P. Cost estimation of point of care B-type natriuretic peptide for the diagnosis of heart failure in the emergency department: Application to Alberta. Information Paper No. 25. Edmonton, AB: Alberta Heritage Foundation for Medical Research (AHFMR); May 2005.
    23. Alberta Heritage Foundation for Medical Research (AHFMR). Efficacy of B-type natriuretic peptide-guided treatment for congestive heart failure. Technote TN 53. Edmonton, AB: AHFMR; 2005.
    24. Mueller C, Laule-Kilian K, Scholer A, et al. B-type natriuretic peptide for acute dyspnea in patients with kidney disease: Insights from a randomized comparison. Kidney Int. 2005;67(1):278-284.
    25. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: Systematic review. BMJ. 2005;330(7492):625.
    26. McKie PM, Burnett JC Jr. B-type natriuretic peptide as a biomarker beyond heart failure: Speculations and opportunities. Mayo Clin Proc. 2005;80(8):1029-1036.
    27. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Bethesda, MD: American College of Cardiology (ACC).; August 2005. Available at: Accessed September 16, 2005.
    28. Craig J, Bradbury I, Cummins E, et al. The use of B-type natriuretic peptides (BNP and NT-proBNP) in the investigation of patients with suspected heart failure. Health Technology Assessment Report 6. Edinburgh, Scotland: NHS Quality Improvement Scotland (NHS QIS); 2005.
    29. Davenport C, Cheng EY, Kwok YT, et al. Assessing the diagnostic test accuracy of natriuretic peptides and ECG in the diagnosis of left ventricular systolic dysfunction: A systematic review and meta-analysis. Br J Gen Pract. 2006;56(522):48-56.
    30. Body R, Roberts C. Best evidence topic report. Brain natriuretic peptide as a potential marker of acute coronary syndromes. Emerg Med J. 2006;23(5):403-407.
    31. Sohne M, Ten Wolde M, Boomsma F, et al. Brain natriuretic peptide in hemodynamically stable acute pulmonary embolism. J Thromb Haemost. 2006;4(3):552-556.
    32. Swedish Council on Technology Assessment in Health Care (SBU). Role of natriuretic peptides in diagnosing heart failure - early assessment briefs (Alert). Stockholm, Sweden; SBU; 2006.
    33. Alberta Heritage Foundation for Medical Research (AHFMR). Prognostic value of B-type natriuretic peptide for congestive heart failure. Technote TN 52. Edmonton, AB: AHRMR; 2006.
    34. Davenport C, Cheng EY, Kwok YT, et al. Assessing the diagnostic test accuracy of natriuretic peptides and ECG in the diagnosis of left ventricular systolic dysfunction: A systematic review and meta-analysis. Br J Gen Pract. 2006;56(522):48-56.
    35. Balion C, Santaguida P, Hill S, et al. Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure. Evidence Report/Technology Assessment No. 142. (Prepared by the McMaster University Evidence-based Practice Center under Contract No. 290-02-0020). AHRQ Publication No. 06-E014. Rockville, MD: Agency for Healthcare Research and Quality.
      September 2006. Available at: Accessed August 14, 2007.
    36. Clerico A, Fontana M, Zyw L, et al. Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: A systematic review. Clin Chem. 2007;53(5):813-822.
    37. Medical Services Advisory Committee (MSAC). B-type natriuretic peptide assays in the diagnosis of heart failure. Part A: In the hospital emergency setting. Part B: In the non-hospital setting. MSAC Application 1087. Canberra, ACT: MSAC; February 2008.
    38. Tang WH, Francis GS, Morrow DA, et al; National Academy of Clinical Biochemistry Laboratory Medicine. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation. 2007;116(5):e99-e109.  
    39. Mark PB, Petrie CJ, Jardine AG. Diagnostic, prognostic, and therapeutic implications of brain natriuretic peptide in dialysis and nondialysis-dependent chronic renal failure. Semin Dial. 2007;20(1):40-49.
    40. Rosner MH. Measuring risk in end-stage renal disease: Is N-terminal pro brain natriuretic peptide a useful marker? Kidney Int. 2007;71(6):481-483.
    41. Gallegos PJ, Maclaughlin EJ, Haase KK. Serial monitoring of brain natriuretic peptide concentrations for drug therapy management in patients with chronic heart failure. Pharmacotherapy. 2008;28(3):343-355.
    42. Rottlaender D, Michels G, Hoppe UC. Natriuretic peptides--when should they be used in heart failure? Dtsch Med Wochenschr. 2008;133(5):196-200.
    43. Hill SA, Balion CM, Santaguida P, et al. Evidence for the use of B-type natriuretic peptides for screening asymptomatic populations and for diagnosis in primary care. Clin Biochem. 2008;41(4-5):240-249.
    44. Oremus M, Raina PS, Santaguida P, et al. A systematic review of BNP as a predictor of prognosis in persons with coronary artery disease. Clin Biochem. 2008;41(4-5):260-265.
    45. Pfisterer M, Buser P, Rickli H, et al; TIME-CHF Investigators. BNP-guided vs symptom-guided heart failure therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301(4):383-392.
    46. Schneider HG, Lam L, Lokuge A, et al. B-type natriuretic peptide testing, clinical outcomes, and health services use in emergency department patients with dyspnea: A randomized trial. Ann Intern Med. 2009;150(6):365-371.
    47. Karthikeyan G, Moncur RA, Levine O, et al. Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies. J Am Coll Cardiol. 2009;54(17):1599-1606.
    48. Bolliger D, Seeberger MD, Filipovic M. Pre-operative cardiac risk assessment in noncardiac surgery: Are natriuretic peptides the magic bullet? J Am Coll Cardiol. 2009;54(17):1607-1608.
    49. Cleland JG, McMurray JJ, Kjekshus J, et al; CORONA Study Group. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: A report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol. 2009;54(20):1850-1859.
    50. Daniels LB, Barrett-Connor E. Can natriuretic peptides help identify heart failure patients for whom statins are beneficial? J Am Coll Cardiol. 2009;54(20):1860-1861.
    51. Porapakkham P, Porapakkham P, Zimmet H, et al. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch Intern Med. 2010;170(6):507-514.
    52. Goei D, Poldermans D. Screening value of N-terminal pro-B-type natriuretic peptide as a predictor of perioperative cardiac events after noncardiac surgery. Future Cardiol. 2010;6(5):603-609.
    53. McKie PM, Cataliotti A, Lahr BD, et al. The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J Am Coll Cardiol. 2010;55(19):2140-2147.
    54. Eurlings LW, van Pol PE, Kok WE, et al. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: Results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol. 2010;56(25):2090-2100.
    55. Troughton RW, Frampton CM, Nicholls MG. Biomarker-guided treatment of heart failure: Still waiting for a definitive answer. J Am Coll Cardiol. 2010;56(25):2101-2104.
    56. Kim HN, Januzzi JL Jr. Natriuretic peptide testing in heart failure. Circulation. 2011;123(18):2015-2019.
    57. Nadir MA, Witham MD, Szwejkowski BR, Struthers AD. Meta-analysis of B-type natriuretic peptide's ability to identify stress induced myocardial ischemia. Am J Cardiol. 2011;107(5):662-667.
    58. Kelder JC, Cowie MR, McDonagh TA, et al. Quantifying the added value of BNP in suspected heart failure in general practice: An individual patient data meta-analysis. Heart. 2011;97(12):959-963.
    59. Pfister R, Sharp S, Luben R, et al. Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: Evidence of causal association from population studies. PLoS Med. 2011;8(10):e1001112.
    60. Takatsuki S, Ivy DD, Nuss R. Correlation of N-terminal fragment of B-type natriuretic peptide levels with clinical, laboratory, and echocardiographic abnormalities in children with sickle cell disease. J Pediatr. 2012;160(3):428-433.
    61. Lin S, Yokoyama H, Rac VE, Brooks SC. Novel biomarkers in diagnosing cardiac ischemia in the emergency department: A systematic review. Resuscitation. 2012;83(6):684-691.
    62. Eindhoven JA, van den Bosch AE, Jansen PR, et al. The usefulness of brain natriuretic peptide in complex congenital heart disease: A systematic review. J Am Coll Cardiol. 2012;60(21):2140-2149.
    63. Rodriguez-Yanez M, Arias-Rivas S, Santamaria-Cadavid M, et al. High pro-BNP levels predict the occurrence of atrial fibrillation after cryptogenic stroke. Neurology. 2013;81(5):444-447.
    64. García-Berrocoso T, Giralt D, Bustamante A, et al.  B-type natriuretic peptides and mortality after stroke: A systematic review and meta-analysis. Neurology. 2013;81(23):1976-1985.
    65. Hijazi Z, Wallentin L, Siegbahn A, et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: Insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol. 2013;61(22):2274-2284.
    66. Roldan V, Vílchez JA, Manzano-Fernandez S, et al. Usefulness of N-terminal pro-B-type natriuretic peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation. Stroke. 2014;45(3):696-701.
    67. Eindhoven JA, Menting ME, van den Bosch AE, et al. Associations between N-terminal pro-B-type natriuretic peptide and cardiac function in adults with corrected tetralogy of Fallot. Int J Cardiol. 2014;174(3):550-556.
    68. Farombi-Oghuvbu I, Matthews T, Mayne PD, et al. N-terminal pro-B-type natriuretic peptide: A measure of significant patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed. 2008;93(4):F257-F260.
    69. Balion C, McKelvie R, Don-Wauchope AC, et al. B-type natriuretic peptide-guided therapy: A systematic review. Heart Fail Rev. 2014;19(4):553-564.
    70. Yang HL, Lin YP, Long Y, et al.  Predicting cardioembolic stroke with the B-type natriuretic peptide test: A systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2014;23(7):1882-1889.
    71. Roberts E, Ludman AJ, Dworzynski K, et al; NICE Guideline Development Group for Acute Heart Failure. The diagnostic accuracy of the natriuretic peptides in heart failure: Systematic review and diagnostic meta-analysis in the acute care setting. BMJ. 2015;350:h910.
    72. Kulkarni M, Gokulakrishnan G, Price J, et al. Diagnosing significant PDA using natriuretic peptides in preterm neonates: A systematic review. Pediatrics. 2015;135(2):e510-e525.
    73. Caplan LR. Clinical diagnosis of stroke subtypes. UpToDate Inc., Waltham, MA. Last reviewed May 2015a.
    74. Caplan LR. Overview of the evaluation of stroke. UpToDate Inc., Waltham, MA. Last reviewed May 2015b.
    75. Phillips JB, III. Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants. UpToDate Inc., Waltham, MA. Last reviewed May 2015.

You are now leaving the Aetna website.

Links to various non-Aetna sites are provided for your convenience only. Aetna Inc. and its subsidiary companies are not responsible or liable for the content, accuracy, or privacy practices of linked sites, or for products or services described on these sites.

Continue >